A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Autor: Linghang Peng, Fangzhu Zhao, Meng Yuan, Xueyong Zhu, Dennis R. Burton, Hejun Liu, Nicholas C. Wu, Chang-Chun D Lee, Marit J. van Gils, David Nemazee, Deli Huang, Sandhya Bangaru, Ian A. Wilson, Hans Christian Kornau, Shawn Barman, Harald Prüss, Rogier W. Sanders, Jakob Kreye, S. Momsen Reincke, Andrew B. Ward
Přispěvatelé: Medical Microbiology and Infection Prevention, AII - Infectious diseases
Rok vydání: 2021
Předmět:
viruses
cross-neutralizing antibody
coronavirus
synergy
3D structure
Antibodies
Viral
Severe Acute Respiratory Syndrome
medicine.disease_cause
metabolism [Angiotensin-Converting Enzyme 2]
chemistry [Antibodies
Viral]
immunology [SARS Virus]
Neutralization
0302 clinical medicine
Pandemic
immunology [SARS-CoV-2]
prevention & control [Severe Acute Respiratory Syndrome]
skin and connective tissue diseases
Coronavirus
0303 health sciences
biology
virus diseases
immunology [Severe acute respiratory syndrome-related coronavirus]
Severe acute respiratory syndrome-related coronavirus
Spike Glycoprotein
Coronavirus
Angiotensin-Converting Enzyme 2
Antibody
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ACE2 protein
human
prevention & control [COVID-19]
Cross Reactions
Microbiology
Article
Antigenic drift
immunology [Antibodies
Viral]
antibody cocktail
chemistry [Antibodies
Neutralizing]
03 medical and health sciences
ddc:570
Virology
medicine
Antigenic variation
Humans
crystallography
030304 developmental biology
SARS-CoV-2
fungi
COVID-19
Antibodies
Neutralizing
immunology [Antibodies
Neutralizing]
body regions
metabolism [Spike Glycoprotein
Coronavirus]
antibody-antigen interaction
biology.protein
Parasitology
030217 neurology & neurosurgery
Zdroj: bioRxiv
article-version (status) pre
article-version (number) 1
Cell host & microbe, 29(5), 806-818.e6. Cell Press
Cell host and microbe 29(5), 806-818.e6 (2021). doi:10.1016/j.chom.2021.04.005
Cell Host & Microbe
ISSN: 1931-3128
DOI: 10.1016/j.chom.2021.04.005
Popis: Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody, CV38-142, in complex with the receptor-binding domains from SARS-CoV-2 and SARS-CoV. Recognition of the N343 glycosylation site and water-mediated interactions facilitate cross-reactivity of CV38-142 to SARS-related viruses, allowing the antibody to accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, notably COVA1-16, to enhance neutralization of SARS-CoV and SARS-CoV-2, including circulating variants of concern B.1.1.7 and B.1.351. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and to protect against zoonotic SARS-related coronaviruses.
Graphical abstract
Antibody CV38-142 from a COVID-19 patient cross-reacts with SARS-related viruses. Liu et al. reveal that CV38-142 interacts with the S309 N343 glycan site and synergizes with COVA1-16 that binds the conserved CR3022 site. Combination of the two cross-neutralizing antibodies shows enhanced neutralization to circulating variants of concern B.1.1.7 and B.1.351.
Databáze: OpenAIRE
Externí odkaz: